Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease. Patients and Methods: We evaluated biological features, treatment recommendations and prognosis for 841 premenopausal patients with pT1-3, pN0 and M0, operated from 1997 to 2001. Results: Patients below 35 years (101, 12%) were more likely to have tumors > 2 cm (35.6% versus 24.2%, P = 0.002), grade 3 (48.5% versus 31.9%, P = 0.009) and with elevated Ki-67 expression (62.4% versus 50.7%, P = 0.002). At the multivariate analysis a statistically significant difference in disease-free survival (DFS, HR 4.44; 95% CI 2.53 to 7.78, P <0.0001), risk of distant metastases (DDFS) (HR 3.23; 95% CI 1.32 to 7.94, P = 0.011) and overall survival (OS) (HR 2.89; 95% CI 1.06 to 7.87, P = 0.038) was observed for younger versus older patients and in the subgroup with endocrine responsive tumors (DFS, HR 5.17, 95% CI 2.72-9.83, P = <0.0001; DDFS, 3.76, 95% CI 1.33-10.6, P = 0.013; OS, 4.71, 95% CI 1.09-20.4, P = 0.039). Conclusions: Compared with less young, very young patients with endocrine responsive and node-negative breast cancer have a worse prognosis. Tailored treatments should be explored in this cohort of patients.

Original languageEnglish
Pages (from-to)1497-1503
Number of pages7
JournalAnnals of Oncology
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Breast Neoplasms
Therapeutics
Survival
Disease-Free Survival
Neoplasms
Multivariate Analysis
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Endocrine responsiveness
  • Prognostic features
  • Very young women

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{2a622b79a6964164ba1d4ef9a758eae2,
title = "Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease",
abstract = "Background: There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease. Patients and Methods: We evaluated biological features, treatment recommendations and prognosis for 841 premenopausal patients with pT1-3, pN0 and M0, operated from 1997 to 2001. Results: Patients below 35 years (101, 12{\%}) were more likely to have tumors > 2 cm (35.6{\%} versus 24.2{\%}, P = 0.002), grade 3 (48.5{\%} versus 31.9{\%}, P = 0.009) and with elevated Ki-67 expression (62.4{\%} versus 50.7{\%}, P = 0.002). At the multivariate analysis a statistically significant difference in disease-free survival (DFS, HR 4.44; 95{\%} CI 2.53 to 7.78, P <0.0001), risk of distant metastases (DDFS) (HR 3.23; 95{\%} CI 1.32 to 7.94, P = 0.011) and overall survival (OS) (HR 2.89; 95{\%} CI 1.06 to 7.87, P = 0.038) was observed for younger versus older patients and in the subgroup with endocrine responsive tumors (DFS, HR 5.17, 95{\%} CI 2.72-9.83, P = <0.0001; DDFS, 3.76, 95{\%} CI 1.33-10.6, P = 0.013; OS, 4.71, 95{\%} CI 1.09-20.4, P = 0.039). Conclusions: Compared with less young, very young patients with endocrine responsive and node-negative breast cancer have a worse prognosis. Tailored treatments should be explored in this cohort of patients.",
keywords = "Breast cancer, Endocrine responsiveness, Prognostic features, Very young women",
author = "Marco Colleoni and N. Rotmensz and G. Peruzzotti and P. Maisonneuve and L. Orlando and R. Ghisini and G. Viale and G. Pruneri and P. Veronesi and A. Luini and M. Intra and A. Cardillo and R. Torrisi and A. Rocca and A. Goldhirsch",
year = "2006",
month = "10",
doi = "10.1093/annonc/mdl145",
language = "English",
volume = "17",
pages = "1497--1503",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease

AU - Colleoni, Marco

AU - Rotmensz, N.

AU - Peruzzotti, G.

AU - Maisonneuve, P.

AU - Orlando, L.

AU - Ghisini, R.

AU - Viale, G.

AU - Pruneri, G.

AU - Veronesi, P.

AU - Luini, A.

AU - Intra, M.

AU - Cardillo, A.

AU - Torrisi, R.

AU - Rocca, A.

AU - Goldhirsch, A.

PY - 2006/10

Y1 - 2006/10

N2 - Background: There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease. Patients and Methods: We evaluated biological features, treatment recommendations and prognosis for 841 premenopausal patients with pT1-3, pN0 and M0, operated from 1997 to 2001. Results: Patients below 35 years (101, 12%) were more likely to have tumors > 2 cm (35.6% versus 24.2%, P = 0.002), grade 3 (48.5% versus 31.9%, P = 0.009) and with elevated Ki-67 expression (62.4% versus 50.7%, P = 0.002). At the multivariate analysis a statistically significant difference in disease-free survival (DFS, HR 4.44; 95% CI 2.53 to 7.78, P <0.0001), risk of distant metastases (DDFS) (HR 3.23; 95% CI 1.32 to 7.94, P = 0.011) and overall survival (OS) (HR 2.89; 95% CI 1.06 to 7.87, P = 0.038) was observed for younger versus older patients and in the subgroup with endocrine responsive tumors (DFS, HR 5.17, 95% CI 2.72-9.83, P = <0.0001; DDFS, 3.76, 95% CI 1.33-10.6, P = 0.013; OS, 4.71, 95% CI 1.09-20.4, P = 0.039). Conclusions: Compared with less young, very young patients with endocrine responsive and node-negative breast cancer have a worse prognosis. Tailored treatments should be explored in this cohort of patients.

AB - Background: There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease. Patients and Methods: We evaluated biological features, treatment recommendations and prognosis for 841 premenopausal patients with pT1-3, pN0 and M0, operated from 1997 to 2001. Results: Patients below 35 years (101, 12%) were more likely to have tumors > 2 cm (35.6% versus 24.2%, P = 0.002), grade 3 (48.5% versus 31.9%, P = 0.009) and with elevated Ki-67 expression (62.4% versus 50.7%, P = 0.002). At the multivariate analysis a statistically significant difference in disease-free survival (DFS, HR 4.44; 95% CI 2.53 to 7.78, P <0.0001), risk of distant metastases (DDFS) (HR 3.23; 95% CI 1.32 to 7.94, P = 0.011) and overall survival (OS) (HR 2.89; 95% CI 1.06 to 7.87, P = 0.038) was observed for younger versus older patients and in the subgroup with endocrine responsive tumors (DFS, HR 5.17, 95% CI 2.72-9.83, P = <0.0001; DDFS, 3.76, 95% CI 1.33-10.6, P = 0.013; OS, 4.71, 95% CI 1.09-20.4, P = 0.039). Conclusions: Compared with less young, very young patients with endocrine responsive and node-negative breast cancer have a worse prognosis. Tailored treatments should be explored in this cohort of patients.

KW - Breast cancer

KW - Endocrine responsiveness

KW - Prognostic features

KW - Very young women

UR - http://www.scopus.com/inward/record.url?scp=33749600677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749600677&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl145

DO - 10.1093/annonc/mdl145

M3 - Article

VL - 17

SP - 1497

EP - 1503

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -